On Thursday, October 27th, Wedbush commenced coverage on shares of Geron in a research note. They assigned the company a “Outperform” rating and a $5.00 Geron stock price target.
Geron stock has an average rating of “Strong Buy” and an average price target of $4.00, as reported by Stock Target Advisor.
Geron Stock Price Performance:
Performance of the Geron Stock Shares of (GERN:NSD) fell $0.05 during Tuesday trading, reaching $2.04. 3.4 million shares of the business were traded, compared to its average volume of 3.121 million.
The company’s market capitalization is $777.72 million, and its P/E ratio is -5.67. Its beta is 0.78. The 52-week low for Geron is $0.99 and the 52-week high is $3.06.
The company’s debt-to-equity ratio is 0.35, while its current ratio and quick ratio are both 2.68. The stock’s 50-day and 200-day moving averages are $2.23 and $2.15, respectively.
Geron Stock-Quarterly Earnings Overview:
Geron (GERN:NSD) announced its most recent quarterly results report on November 3rd. The biopharmaceutical company’s quarterly earnings per share (EPS) came in at ($0.10), missing the consensus estimate of ($0.09) by ($0.01).
The company’s quarterly sales was $0.30 million, exceeding analysts’ projections of $0.12 million. Geron’s return on equity was -110.76 percent, while its net margin was -8,568.0 percent.
Equity research analysts expect that Geron will report an EPS of -0.38 for the current fiscal year.
Institutional Holdings:
Several hedge funds and other institutional investors have adjusted their positions in the company in recent months.
In the second quarter, Bioimpact Capital LLC increased its holding in Geron by 37.2%. Bioimpact Capital LLC now holds 8,434,991 shares of the biopharmaceutical company’s stock worth $13,074,000 after acquiring an additional 2,285,721 shares in the preceding quarter.
Logos Global Management LP acquired a $4,680,000 investment in Geron shares during the third quarter.
During the first quarter, Vanguard Group Inc. increased its holdings in shares of Geron by 12.4%. After acquiring an additional 1,910,182 shares during the preceding quarter, Vanguard Group Inc. now owns 17,336,930 shares of the biopharmaceutical Geron stock worth $23,579,000.
The position of State Street Corporation in Geron increased by 13.4% in the first quarter. State Street Corp now holds 13,518,850 shares of the biopharmaceutical company’s stock, valued at $18,386,000, after acquiring an additional 1,593,886 shares in the last recent quarter.
In the second quarter, Healthcare of Ontario Pension Plan Trust Fund purchased a new holding in Geron for $1,252,000.
Institutional investors and hedge funds hold 49.75% of the Geron stock.
Company Profile:
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
The company was incorporated in 1990 and is headquartered in Foster City, California.
